PT - JOURNAL ARTICLE AU - Ferreira, Pâmela C. L AU - Ferrari-Souza, João Pedro AU - Tissot, Cécile AU - Bellaver, Bruna AU - Leffa, Douglas T. AU - Lussier, Firoza Z. AU - Povala, Guilherme AU - Therriault, Joseph AU - Benedet, Andrea L. AU - Ashton, Nicholas J. AU - Cohen, Ann D. AU - Lopez, Oscar L. AU - Tudorascu, Dana L. AU - Klunk, William E. AU - Soucy, Jean-Paul AU - Gauthier, Serge AU - Villemagne, Victor L. AU - Zetterberg, Henrik AU - Blennow, Kaj AU - Rosa-Neto, Pedro AU - Zimmer, Eduardo R AU - Karikari, Thomas K. AU - Pascoal, Tharick A. AU - , TI - Potential utility of plasma p-tau and NfL as surrogate biomarkers for preventive clinical trials AID - 10.1101/2022.08.17.22278853 DP - 2022 Jan 01 TA - medRxiv PG - 2022.08.17.22278853 4099 - http://medrxiv.org/content/early/2022/08/18/2022.08.17.22278853.short 4100 - http://medrxiv.org/content/early/2022/08/18/2022.08.17.22278853.full AB - Background Although longitudinal changes in plasma phosphorylated tau 181 (p-tau181) and neurofilament light (NfL) correlate with Alzheimer’s disease (AD) progression, it is unknown whether these changes can be used to monitor drug effects in preventive clinical trials. Here, we tested the utility of changes in plasma p-tau181 and NfL as surrogate biomarkers for clinical trials focusing on cognitively unimpaired (CU) individuals.Methods We evaluated 257 CU older individuals with amyloid-beta (Aβ) positron emission tomography (PET) at baseline, as well as the baseline, up to 24-month plasma p-tau181 and NfL measures. Linear regressions and Cox-proportional hazards tested the associations of change in markers with age and clinical progression, respectively. We estimated the sample size needed to test a 25% drug effect with 80% of power at a 0.05 level on reducing changes in plasma markers.Results Longitudinal changes in plasma NfL were associated with age, while changes in plasma p-tau181 with progression to amnestic MCI. Clinical trial using p-tau181 and NfL would require 78% and 63% smaller sample sizes, respectively, for a 24-month than a 12-month follow-up. The use of Aβ positivity for enrichment had a larger impact on reducing the sample size required for trials using p-tau181 (43% reduction) than NfL (17%) as surrogate. Notably, population enrichment with intermediate levels of Aβ, rather than merely Aβ positivity, reduced the sample size by 88% for p-tau181 and 64% for NfL over 12 months, and by 73% for p-tau181 and 59% for NfL over 24 months.Conclusion Our results highlighted that changes in plasma NfL could be used as a surrogate for age-related degeneration, while longitudinal changes in plasma p-tau181 were associated with parallel clinical progression. A follow-up duration of 24 months was associated with more stable changes in plasma measures and, consequently, a greater effect size than a follow-up period of 12 months. The enrollment of CU subjects with intermediate levels of Aβ constitutes the alternative with the largest effect size for clinical trials quantifying plasma p-tau181 and NfL over 12 and 24 months.Competing Interest StatementDetails of the competing interests are described on the manuscriptFunding StatementAll fundings of this study are described on the main manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data used in the preparation of the present manuscript is publicly available for download at http://adni.loni.usc.eduI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.